QPS invites you to participate in our next preclinical Webinar. Please scroll down to choose from several available dates and times.

Meet the Speaker

Sandra Henkelman, PhD

Team Lead TLM, QPS Netherlands

In 2011, Sandra Henkelman obtained her PhD degree in Biomedical Engineering at the University of Groningen in the Netherlands. After a 4-year Post doc at the European Research Institute for the Biology of Ageing, she joined QPS Netherlands in 2016. She is currently a Team Lead TLM and supports the method development, validation, and sample analysis in the department of ligand binding assays and FACS assays.

Overview

Oligonucleotides have been utilized for the last two decades for their therapeutic properties. Majorly these are used either for inhibition of genes or protein expression. Oligonucleotide drugs include several classes, such as antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), microRNAs (miRNAs) and aptamers. As oligonucleotide drugs gain popularity, analysis of oligonucleotides has become an important element of drug development. It is our experience that different bioanalysis platforms are needed for the different types of oligonucleotide drugs, depending on their size, chemistry and complexity.

In this webinar, we will discuss the analysis of oligonucleotides by hybridization ELISA assay. In this assay format, the antigen ligand and antibodies in ELISA are replaced with labelled complementary capture and detection oligonucleotide probes. These probes are designed in our labs to maximize affinity with the target oligonucleotide, while reducing the potential for self-annealing. Assessing the biodistribution of oligonucleotides is a crucial part of any preclinical development program. In this webinar, we will go into the development and qualification of methods for the analysis of oligonucleotides in various tissues.

For your convenience, we are offering this webinar on two different dates/times. Please register for one of the options below.